Compass Pathways (NASDAQ:CMPS) Sets New 52-Week High – Should You Buy?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) shares reached a new 52-week high on Tuesday . The stock traded as high as $10.21 and last traded at $9.46, with a volume of 39615724 shares trading hands. The stock had previously closed at $6.66.

Wall Street Analyst Weigh In

Several research firms have commented on CMPS. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Morgan Stanley lowered their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Royal Bank Of Canada increased their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. HC Wainwright increased their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Canaccord Genuity Group lowered their price objective on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.63.

Compass Pathways Stock Down 5.4%

The business’s fifty day moving average is $6.54 and its two-hundred day moving average is $6.42. The company has a market cap of $1.13 billion, a P/E ratio of -2.83 and a beta of 2.01. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). Equities analysts predict that Compass Pathways PLC Sponsored ADR will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC grew its position in shares of Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after buying an additional 1,200 shares during the last quarter. CWM LLC grew its position in shares of Compass Pathways by 19.2% in the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock worth $90,000 after buying an additional 2,525 shares during the last quarter. Conservest Capital Advisors Inc. grew its position in shares of Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after buying an additional 5,000 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Compass Pathways in the 4th quarter worth approximately $38,000. Finally, Raymond James Financial Inc. grew its position in shares of Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after buying an additional 6,228 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.